Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

Nathalie A. Johnson; Pier Luigi Zinzani; Eva Domingo‐Doménech; Joshua Brody; Justin Kline; Bijal Shah; Amitkumar Mehta; Hervé Ghesquières; Kerry J. Savage; Paul M. Barr; Armando Santoro; Silvia Ferrari; David Cunningham; Graham P. Collins; Michelle A. Fanale; Jennifer Krajewski; Alev Akyol; Russell Crowe; Rachael Wen; John Kuruvilla

doi:10.1080/14796694.2025.2599082

Abstract

Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.

Affiliated Institutions

Related Publications

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell , Alexander M. Lesokhin , Ivan Borrello +16 more

Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chro...

2014 New England Journal of Medicine 3484 citations

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson , M. Lia Palomba , Leo I. Gordon +19 more

Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel in pa...

2020 The Lancet 2118 citations

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster , Michael Bishop , Constantine S. Tam +21 more

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...

2018 New England Journal of Medicine 3775 citations

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy , Chip Stewart , Andrew Dunford +43 more

Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is a clinically and genetically heterogeneous disease that is further classified into trans...

2018 Nature Medicine 1852 citations

ID3 mutations are recurrent events in double-hit B-cell lymphomas.

Niklas Gebauer , Veronica Bernard , Alfred C. Feller +1 more

Double-hit lymphomas (DHL) with chromosomal rearrangements affecting the avian myelocytomatosis viral oncogene homolog (cMYC) and either the B-cell lymphoma-2 (BCL2) or -6 (BCL6...

2013 PubMed 25 citations

Publication Info

Year: 2025
Type: article
Pages: 1-7
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Nathalie A. Johnson, 
                                
                                    Pier Luigi Zinzani, 
                                
                                    Eva Domingo‐Doménech
                                
                                et al.
                            
                            (2025). 
                            Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma. 
                            Future Oncology
                            
                            , 1-7.
                            https://doi.org/10.1080/14796694.2025.2599082

Identifiers

DOI: 10.1080/14796694.2025.2599082